戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 f vaccination with >2 doses of measles-mumps-rubella vaccine.
2 nths of age on the immunogenicity of measles-rubella vaccine.
3 ic conditions in women receiving the RA 27/3 rubella vaccine.
4 o-administered with yellow fever and measles-rubella vaccines.
5  since the widespread use of the measles and rubella vaccines.
6           No IPTT received the measles-mumps-rubella vaccine; 1 IPTT received the yellow fever vaccin
7 ults, we summarize the safety of introducing rubella vaccine across demographic and coverage contexts
8 accine to the incorporation of measles-mumps-rubella vaccine administered in the routine program.
9 mine seroconversion rates with measles-mumps-rubella vaccine administered to children at 9, 12, or 15
10 f seizures compared with measles, mumps, and rubella vaccine administered with or without varicella v
11 (measles-rubella plus LJEV group) or measles-rubella vaccine alone (measles-rubella group).
12 ed States, including (1) measles, mumps, and rubella vaccine and autism; (2) thimerosal, a mercury-ba
13 cted and geocoded tweets about measles-mumps-rubella vaccine and classified their sentiment using mac
14                            In China, measles-rubella vaccine and live attenuated SA 14-14-2 Japanese
15 mly assigned (1:1) to receive either measles-rubella vaccine and LJEV simultaneously (measles-rubella
16  at the same time they receive measles-mumps-rubella vaccine and may be given at the same time as oth
17                          One dose of measles-rubella vaccine at age 15 months closed the remaining me
18  measles vaccine at age 9 months and measles-rubella vaccine at age 15 months.
19 (MCV-A) at 15 months, in addition to measles-rubella vaccine at both 9 and 15 months.
20 vaccinated populations (2-dose measles-mumps-rubella vaccine coverage >=85%).
21                              Although global rubella vaccine coverage reached only 70% in 2020 global
22                  Immune responses to current rubella vaccines demonstrate significant inter-individua
23 ines were co-administered with a measles and rubella vaccine (first dose) and a yellow fever vaccine
24 ncreased risk was associated with receipt of rubella vaccine for any outcome except for prevalence of
25                       The MMR (measles/mumps/rubella) vaccine has been one of the safest and most eff
26 andard for anti-rubella IgG (RUBI-1-94), new rubella vaccines have been developed and global coverage
27 22) genes were significantly associated with rubella vaccine humoral immunity.
28 rease the body of knowledge on the safety of rubella vaccine if an unknowingly pregnant woman is vacc
29 and adolescents aged 1-19 years with measles-rubella vaccine in support of achieving the Region of th
30 ates due to concerns about the measles-mumps-rubella vaccine in the UK, and increasing numbers of cas
31 a causal relationship between currently used rubella vaccine in the US and some chronic arthropathy w
32 1 alleles were significantly associated with rubella vaccine-induced antibodies.
33                                              Rubella vaccine-induced granulomas are a novel phenotype
34 ammatory genes that may assist in explaining rubella vaccine-induced immune response variations.
35 etic polymorphisms play an important role in rubella vaccine-induced immunity.
36 immunogenetic understanding of mechanisms of rubella vaccine-induced immunity.
37 provide guidance on the safe introduction of rubella vaccine into countries in the face of substantia
38 s that countries considering introduction of rubella vaccine into their immunisation programme assess
39                              Measles, mumps, rubella vaccine is recommended for both adult and pediat
40 a vaccine soon after the measles, mumps, and rubella vaccine (<28 days), and in children who received
41 ccine (V) dose given after one measles-mumps-rubella vaccine (MMR) dose (MMR + V), versus two MMR dos
42                        A third measles-mumps-rubella vaccine (MMR) dose (MMR3) is recommended in the
43 accination with the live measles, mumps, and rubella vaccine (MMR) is associated with a lower rate of
44                          Measles, mumps, and rubella vaccine (MMR) or immune globulin (IG) are routin
45  and safety of a third dose of measles-mumps-rubella vaccine (MMR-3) in 150 young adults.
46 have received a second dose of measles-mumps-rubella vaccine (MMR2) at kindergarten entry.
47 have received a second dose of measles-mumps-rubella vaccine (MMR2) at kindergarten entry.
48                A third dose of measles-mumps-rubella vaccine (MMR3) is recommended in mumps outbreak
49          A third dose of measles, mumps, and rubella vaccine (MMR3) may be administered in outbreak a
50 A were offered a third dose of measles-mumps-rubella vaccine (MMR3), and serum specimens were obtaine
51 ity of concomitant administration of measles-rubella vaccine (MR) and a third dose of human rotavirus
52  safety, and immunogenicity of a measles and rubella vaccine (MRV)-MNP in children.
53  high coverage(>95%) with 2 doses of measles-rubella vaccine needs to be maintained, measles-rubella
54         No association between measles/mumps/rubella vaccine or thimerosal-containing pertussis vacci
55 In 2000, the first World Health Organization rubella vaccine position paper was published to guide in
56                      Use of combined measles-rubella vaccines provides an opportunity to eliminate ru
57 regnancy is a contraindication of receipt of rubella vaccine (RCV).
58 exposed to the live-attenuated measles-mumps-rubella vaccine regardless of route of administration.
59 accine at age 9 months or with a measles and rubella vaccine (second dose) at age 15 months.
60 of risk of CRS associated with administering rubella vaccine shortly before or during pregnancy.
61 safety with co-administered LJEV and measles-rubella vaccines supports the co-administration of these
62 nts who were vaccinated (measles, mumps, and rubella vaccine/tick-borne encephalitis vaccine/BCG vacc
63 ter inactivated poliovirus and measles-mumps-rubella vaccines to patients younger than 7 years than t
64 the capacity of immunoglobulin to neutralize rubella vaccine virus and 4 VDRV strains.
65                             As expected, the rubella vaccine virus itself was potently neutralized by
66 nd the defective effector mechanism allowing rubella vaccine virus persistence in granulomas.
67 y as a key effector mechanism for control of rubella vaccine virus, without evidence for its need in
68     Estimated national coverage with measles-rubella vaccine was 79.2% (95% confidence interval, 77.6
69                                      Measles-rubella vaccine was introduced into the country's routin
70 spective immunogenicity trial of measles and rubella vaccines was conducted in Oman.
71 negative adults immunized with measles-mumps-rubella vaccine were studied.
72 nical trial (NCT01681992) of 2 measles-mumps-rubella vaccines were used to compare anti-mumps antibod
73 fied, additional mass campaigns with measles-rubella vaccine will be necessary.